Is the 250% Carisma Therapeutics Stock (CARM) Surge a Sucker's Rally?
Carisma Therapeutics (CARM) stock underwent a massive rally on Tuesday despite a lack of news from the biopharmaceutical company. This may have investors wondering what's going on with CARM stock today.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
It appears that Carisma Therapeutics stock saw a 'sucker's rally' or 'dead cat bounce' today. This is when a stock that has suffered strong negative momentum undergoes an unexpected rally. While that might see some traders take interest in CARM stock, they should first note that the company is considering strategic alternatives, including the potential wind-down of its operations.
CARM stock was up 247.71% during pre-market trading on Tuesday. However, the stock has dropped 46% year-to-date and 81.71% over the past 12 months.
Is Carisma Therapeutics Stock a Buy, Sell, or Hold?
Spark, TipRanks' AI analyst, rates Carisma Therapeutics stock an Underperform (40) with no price target. The company faces 'significant financial challenges, as evidenced by its poor financial performance and valuation metrics.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Core Scientific could get north of $30/share in buyout, says Cantor Fitzgerald
According to a report, CoreWeave (CRWV) is in advanced talks to buy Core Scientific (CORZ), a deal that could be reached in the coming weeks, Cantor Fitzgerald analyst Brett Knoblauch tells investors. The firm says the acquisition makes sense from a pure ROI perspective for CoreWeave, and that if it were to happen, Core Scientific could get north of $30/share when accounting for value of data center infrastructure, but if CoreWeave uses all stock, that could raise the acquisition price. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on CORZ: Disclaimer & DisclosureReport an Issue JPMorgan continues to recommend Riot after Core Scientific report Strategic Acquisition and Capacity Expansion Drive Buy Rating for Core Scientific Inc. M&A News: CoreWeave (CRWV) Is Reportedly in Talks to Acquire Core Scientific Closing Bell Movers: Nike gains 10% on more positive earnings call Core Scientific deal could be at over $30 per share, says Cantor Fitzgerald
Yahoo
2 hours ago
- Yahoo
Utz Brands price target lowered to $16 from $17 at Barclays
Barclays lowered the firm's price target on Utz Brands (UTZ) to $16 from $17 and keeps an Overweight rating on the shares. The firm says that despite the ongoing salty snack category 'malaise,' it has remained bullish on Utz shares, believing the company's growth is far less reliant on overall category growth trends given its 'significant idiosyncratic whitespace distribution opportunities' in its expansion markets. The analyst remains 'encouraged' with recent measured channel tracking data but shifted some EBITDA from Q2 to the second half of 2025 to better reflect Utz's phasing of investment spend and year ago comparisons. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on UTZ: Disclaimer & DisclosureReport an Issue DA Davidson analysts hold an analyst/industry conference call Utz Brands director buys $199.3K in common stock Utz Brands price target lowered to $13.50 from $15 at UBS Cautious Outlook for UTZ Brands Amid Market Concerns and Weak Demand Trends Buy Rating for UTZ Brands: Strong Financial Performance and Strategic Initiatives Drive Positive Outlook Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
B. Riley Financial announces $117.8M sale of GlassRatner to TorQuest Partners
B. Riley Financial (RILY) announced it has sold its advisory services business, GlassRatner Advisory & Capital Group and B. Riley Farber Advisory, to funds managed by TorQuest Partners for $117.8M. BRF expects to record a gain on the sale of GlassRatner, which it acquired in August 2018, of approximately $66M. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on RILY: Disclaimer & DisclosureReport an Issue Largest borrow rate increases among liquid names B Riley Financial Receives Nasdaq Compliance Extension B. Riley Financial granted extension from Nasdaq regarding listing rules B Riley Financial Faces Nasdaq Delinquency Notification B. Riley Financial receives expected delinquency notification from Nasdaq
